Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity

British Journal of Pharmacology

Volumn 170, Issue 7, 2013, Pages 1333-1348

  Boughton, C K ^a   Murphy, K G ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

anorectic; hypothalamus; neuropeptides; obesity; orexigenic

Indexed keywords

2 [1 (3 CHLORO 5 ISOPROPOXYCARBONYLAMINOPHENYL)ETHYLAMINO] 6 [2 (5 ETHYL 4 METHYL 2 THIAZOLYL)ETHYL] 4 MORPHOLINOPYRIDINE; ALB 127158; AMFEBUTAMONE PLUS NALTREXONE; AZD 2820; BMS 193885; BMS 830216; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; DAPICLERMIN; GALANIN LIKE PEPTIDE; LORCASERIN; MELANIN CONCENTRATING HORMONE RECEPTOR 1 ANTAGONIST; MELANOCORTIN; MK 0557; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NGD 4715; NGD 951; OREXIN; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; RELAXIN 3; RM 493; SIBUTRAMINE; SUVOREXANT; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELNEPERIT; Y 1 718; ANTIOBESITY AGENT;

ALLERGIC REACTION; BIRTH DEFECT; BODY WEIGHT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENERGY EXPENDITURE; ERYTHROCYTE COUNT; FOOD INTAKE; HEADACHE; HEART PALPITATION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HIP CIRCUMFERENCE; HOMEOSTASIS; HUMAN; LIFESTYLE MODIFICATION; LOW CALORY DIET; MEMORY DISORDER; METABOLIC RATE; MOTOR NEURON DISEASE; NONHUMAN; NUTRITIONAL STATUS; OBESITY; PEPTIDERGIC NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER; SUICIDAL IDEATION; WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; BRAIN; DRUG COMBINATION; DRUG EFFECTS; FEEDING BEHAVIOR; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; APPETITE REGULATION; BODY WEIGHT; BRAIN; DRUG THERAPY, COMBINATION; FEEDING BEHAVIOR; HUMANS; NEUROPEPTIDES; OBESITY; SIGNAL TRANSDUCTION;

EID: 84887656219     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12037     Document Type: Review

References (203)

1. Actelion (2011). Actelion and GSK discontinue clinical development of Almorexant [press release], 28 January 2011. Available at: http://www.actelion. com/en/investors/media-releases/index.page?newsId=1483135 (accessed 15 August 2012).
2. Adan RA, Oosterom J, Ludvigsdottir G, Brakkee JH, Burbach JP, Gispen WH, (1994). Identification of antagonists for melanocortin MC3, MC4 and MC5 receptors. Eur J Pharmacol 269: 331-337.
3. Alexander SPH, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edition (2011). Br J Pharmacol 164 (Suppl. 1): S1-S324.
4. Allen JM, Yeats JC, Adrian TE, Bloom SR, (1984). Radioimmunoassay of neuropeptide Y. Regul Pept 8: 61-70.
5. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. (2012). Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 20: 330-342.
6. AMRI (2011). Available pipeline programs-obesity: MCH-1 antagonist program. [online] Available at: http://www.amriglobal.com/products-and-services/ products-detail.cfm?prodID=7&subServID=67 (accessed 15 August 2012).
7. Antal-Zimanyi I, Bruce MA, LeBoulluec KL, Iben LG, Mattson GK, McGovern RT, et al. (2008). Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y1 receptor antagonist. Eur J Pharmacol 590: 224-232.
8. Aston-Jones G, Smith RJ, Sartor GC, Moorman DE, Massi L, Tahsili-Fahadan P, et al. (2010). Lateral hypothalamic orexin/hypocretin neurons: a role in reward-seeking and addiction. Brain Res 1314: 74-90.
9. Bai FL, Yamano M, Shiotani Y, Emson PC, Smith AD, Powell JF, et al. (1985). An arcuato-paraventricular and -dorsomedial hypothalamic neuropeptide Y-containing system which lacks noradrenaline in the rat. Brain Res 331: 172-175.
10. Banks WA, (2006). The blood-brain barrier as a regulatory interface in the gut-brain axes. Physiol Behav 89: 472-476.
11. Bathgate RAD, Samuel CS, Burazin TCD, Layfield S, Claasz AA, Reytomas IGT, et al. (2002). Human relaxin gene 3 (H3) and the equivalent mouse relaxin (M3) gene. J Biol Chem 277: 1148-1157.
12. Bertagna X, (1994). Proopiomelanocortin-derived peptides. Endocrinol Metab Clin North Am 23: 467-485.
13. Bewick GA, Gardiner JV, Dhillo WS, Kent AS, White NE, Webster Z, et al. (2005). Postembryonic ablation of AgRP neurons in mice leads to a lean, hypophagic phenotype. FASEB J 19: 1680-1682.
14. Biebermann H, Krude H, Elsner A, Chubanov V, Gudermann T, Grüters A, (2003). Autosomal-dominant mode of inheritance of a melanocortin-4 receptor mutation in a patient with severe early-onset obesity is due to a dominant-negative effect caused by receptor dimerization. Diabetes 52: 2984-2988.
15. Bittencourt JC, Presse F, Arias C, Peto C, Vaughan J, Nahon JL, et al. (1992). The melanin-concentrating hormone system of the rat brain: an immuno- and hybridization histochemical characterization. J Comp Neurol 319: 218-245.
16. Blomqvist AG, Herzog H, (1997). Y-receptor subtypes-how many more? Trends Neurosci 20: 294-298.
17. Borowsky B, Durkin MM, Ogozalek K, Marzabadi MR, DeLeon J, Heurich R, et al. (2002). Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med 8: 825-830.
18. Bray GA, (1992). Pathophysiology of obesity. Am J Clin Nutr 55: 488S-494S.
19. Broberger C, Johansen J, Johansson C, Schalling M, Hökfelt T, (1998). The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proc Natl Acad Sci U S A 95: 15043-15048.
20. Brothers SP, Wahlestedt C, (2010). Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Mol Med 2: 429-439.
21. Burazin TCD, Bathgate RAD, Macris M, Layfield S, Gundlach AL, Tregear GW, (2002). Restricted, but abundant, expression of the novel rat gene-3 (R3) relaxin in the dorsal tegmental region of brain. J Neurochem 82: 1553-1557.
22. Butler AA, Kesteson RA, Khong K, Cullen MJ, Pelleymounter MA, Dekoning J, et al. (2000). A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 141: 3518-3521.
23. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, et al. (1999). Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98: 437-451.
24. Chen AS, Metzger JM, Trumbauer ME, Xm G, Yu H, Frazier EG, et al. (2000). Role of the melanocortin-4 receptor in metabolic rate and food intake in mice. Transgenic Res 9: 145-154.
25. Chen J, Kuei C, Sutton SW, Bonaventure P, Nepomuceno D, Eriste E, et al. (2005). Pharmacological characterization of relaxin-3/INSL7 receptors GPCR135 and GPCR142 from different mammalian species. J Pharmacol Exp Ther 312: 83-95.
26. Cheung CC, Clifton DK, Steiner RA, (1997). Proopiomelanocortin neurons are direct targets for leptin in the hypothalamus. Endocrinology 138: 4489-4492.
27. Chronwall BM, DiMaggio DA, Massari VJ, Pickel VM, Ruggiero DA, O'Donohue TL, (1985). The anatomy of neuropeptide-y-containing neurons in rat brain. Neuroscience 15: 1159-1181.
28. Clapham JC, Arch JRS, Tadayyon M, (2001). Anti-obesity drugs: a critical review of current therapies and future opportunities. Pharmacol Ther 89: 81-121.
29. Clark JT, Kalra PS, Crowley WR, Kalra SP, (1984). Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 115: 427-429.
30. ClinicalTrials.gov (2011). Safety study of the inhibition of Agouti-related Protein (AgRP) for the management of obesity and weight loss. [online] Available at: http://clinicaltrials.gov/ct2/results?term=TTP-435 (accessed 15 August 2012).
31. Cone RD, Cowley MA, Butler AA, Fan W, Marks DL, Low MJ, (2001). The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord 25 (Suppl. 5): S63-S67.
32. Conner JM, Lauterborn JC, Yan Q, Gall CM, Varon S, (1997). Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. J Neurosci 17: 2295-2313.
33. Contreras RJ, Kosten T, Bird E, (1984). Area postrema: part of the autonomic circuitry of caloric homeostasis. Fed Proc 43: 2966-2968.
34. Cordeira J, Rios M, (2011). Weighing in the role of BDNF in the central control of eating behavior. Mol Neurobiol 44: 441-448.
35. Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ, et al. (2010). Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl] [5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of Insomnia. J Med Chem 53: 5320-5332.
36. Criscione L, Rigollier P, Batzl-Hartmann C, Rüeger H, Stricker-Krongrad A, Wyss P, et al. (1998). Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J Clin Invest 102: 2136-2145.
37. Daniels AJ, Grizzle MK, Wiard RP, Matthews JE, Heyer D, (2002). Food intake inhibition and reduction in body weight gain in lean and obese rodents treated with GW438014A, a potent and selective NPY-Y5 receptor antagonist. Regul Pept 106: 47-54.
38. Date Y, Ueta Y, Yamashita H, Yamaguchi H, Matsukura S, Kangawa K, et al. (1999). Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci U S A 96: 748-753.
39. Della-Zuana O, Presse F, Ortola C, Duhault J, Nahon JL, Levens N, (2002). Acute and chronic administration of melanin-concentrating hormone enhances food intake and body weight in Wistar and Sprague-Dawley rats. Int J Obes Relat Metab Disord 26: 1289-1295.
40. Edwards CM, Abusnana S, Sunter D, Murphy KG, Ghatei MA, Bloom SR, (1999). The effect of the orexins on food intake: comparison with neuropeptide Y, melanin-concentrating hormone and galanin. J Endocrinol 160: R7-12.
41. Elias CF, Lee C, Kelly J, Aschkenasi C, Ahima RS, Couceyro PR, et al. (1998a). Leptin activates hypothalamic CART neurons projecting to the spinal cord. Neuron 21: 1375-1385.
42. Elias CF, Saper CB, Maratos-Flier E, Tritos NA, Lee C, Kelly J, et al. (1998b). Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. J Comp Neurol 402: 442-459.
43. Elmquist JK, Elias CF, Saper CB, (1999). From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 22: 221-232.
44. EMEA (2006). Guideline on clinical investigation of medicinal products used in weight control. [online] Available at: http://www.ema.europa.eu/docs/en- GB/document-library/Scientific-guideline/2009/09/WC500003213.pdf (accessed 15 August 2012).
45. Erickson JC, Clegg KE, Palmiter RD, (1996). Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 381: 415-421.
46. Erondu N, Gantz I, Musser B, Suryawanshi S, Mallick M, Addy C, et al. (2006). Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 4: 275-282.
47. Erondu N, Addy C, Lu K, Mallick M, Musser B, Gantz I, et al. (2007a). NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine. Obesity 15: 2027-2042.
48. Erondu N, Wadden T, Gantz I, Musser B, Nguyen AM, Bays H, et al. (2007b). Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity 15: 895-905.
49. Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, McIlwain HH, Heymsfield SB, et al. (2003). Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 289: 1826-1832.
50. FDA (2007). Guidance for industry-developing products for weight management. [online] Available at: http://www.fda.gov/downloads/Drugs/./ Guidances/ucm071612.pdf (accessed 15 August 2012).
51. FDA (2012). FDA approves weight-management drug Qsymia. [press release], 17 July 2012. Available at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm312468.htm (accessed 15 August 2012).
52. Fehm HL, Smolnik R, Kern W, McGregor GP, Bickel U, Born J, (2001). The melanocortin melanocyte-stimulating hormone/adrenocorticotropin4-10 decreases body fat in humans. J Clin Endocrinol Metab 86: 1144-1148.
53. Fermini B, Fossa AA, (2003). The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov 2: 439-447.
54. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al. (2011). A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 96: 3067-3077.
55. Flach S, Williams E, Leonard L, Kochan R, Palleja S, Paul R, et al. (2007). Clinical safety and tolerability of S-2367 at doses up to 9600mg/day administered orally once a day for 7 days with an FDA high-fat caloric equivalent breakfast in healthy overweight and obese male and female subjects. The Obesity Society's 2007 Annual Scientific Meeting, October 20-24, New Orleans, Louisiana.
56. Fong TM, Mao C, MacNeil T, Kalyani R, Smith T, Weinberg D, et al. (1997). ART (protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors. Biochem Biophys Res Commun 237: 629-631.
57. Foresight Report (2007). Tackling obesities: future choices. [online] Available at: http://www.bis.gov.uk/foresight/our-work/projects/published- projects/tackling-obesities/reports-and-publications (accessed 15 August 2012).
58. Fraley GS, Scarlett JM, Shimada I, Teklemichael DN, Acohido BV, Clifton DK, et al. (2004). Effects of diabetes and insulin on the expression of galanin-like peptide in the hypothalamus of the rat. Diabetes 53: 1237-1242.
59. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. (2011). Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 377: 1341-1352.
60. Gardiner JV, Kong WM, Ward H, Murphy KG, Dhillo WS, Bloom SR, (2005). AAV mediated expression of anti-sense neuropeptide Y cRNA in the arcuate nucleus of rats results in decreased weight gain and food intake. Biochem Biophys Res Commun 327: 1088-1093.
61. Gautron L, Elmquist JK, (2011). Sixteen years and counting: an update on leptin in energy balance. J Clin Invest 121: 2087-2093.
62. Gloaguen I, Costa P, Demartis A, Lazzaro D, Di Marco A, Graziani R, et al. (1997). Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc Natl Acad Sci U S A 94: 6456-6461.
63. Glover ID, Barlow DJ, Pitts JE, Wood SP, Tickle IJ, Blundell TL, et al. (1984). Conformational studies on the pancreatic polypeptide hormone family. Eur J Biochem 142: 379-385.
64. Gomori A, Ishihara A, Ito M, Mashiko S, Matsushita H, Yumoto M, et al. (2003). Chronic intracerebroventricular infusion of MCH causes obesity in mice. Am J Physiol Endocrinol Metab 284: E583-E588.
65. Graham M, Shutter JR, Sarmiento U, Sarosi I, Stark KL, (1997). Overexpression of Agrt leads to obesity in transgenic mice. Nat Genet 17: 273-274.
66. Gray J, Yeo GS, Cox JJ, Morton J, Adlam AL, Keogh JM, et al. (2006). Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. Diabetes 55: 3366-3371.
67. Greenfield JR, (2011). Melanocortin signalling and the regulation of blood pressure in human obesity. J Neuroendocrinol 23: 186-193.
68. Greenway FL, Caruso MK, (2005). Safety of obesity drugs. Expert Opin Drug Saf 4: 1083-1095.
69. Greenway FL, Dunayevich E, Tollefson G, Erickson J, Guttadauria M, Fujioka K, et al. (2009). Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 94: 4898-4906.
70. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376: 595-605.
71. Griffith DA, Hargrove DM, Maurer TS, Blum CA, De Lombaert S, Inthavongsay JK, et al. (2011). Discovery and evaluation of pyrazolo[1,5-a]pyrimidines as neuropeptide Y1 receptor antagonists. Bioorg Med Chem Lett 21: 2641-2645.
72. Gropp E, Shanabrough M, Borok E, Xu AW, Janoschek R, Buch T, et al. (2005). Agouti-related peptide-expressing neurons are mandatory for feeding. Nat Neurosci 8: 1289-1291.
73. Guzzo P, Surman M, Luche M, Hadden M, Henderson A, Jiang XW, et al. (2010). Pharmacology of ALB-127158(a), an antagonist of the MCH1 receptor for the treatment of obesity. Obesity 2010 28th Annual Scientific Meeting; San Diego, CA.
74. Hahn TM, Breininger JF, Baskin DG, Schwartz MW, (1998). Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurosci 1: 271-272.
75. Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE, (2007). Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 67: 27-55.
76. Hallschmid M, Smolnik R, McGregor G, Born J, Fehm HL, (2006). Overweight humans are resistant to the weight-reducing effects of melanocortin4-10. J Clin Endocrinol Metab 91: 522-525.
77. Han JC, Liu QR, Jones M, Levinn RL, Menzie CM, Jefferson-George KS, et al. (2008). Brain-derived neurotrophic factor and obesity in the WAGR syndrome. N Engl J Med 359: 918-927.
78. Harris GC, Wimmer M, Aston-Jones G, (2005). A role for lateral hypothalamic orexin neurons in reward seeking. Nature 437: 556-559.
79. Hauptman JB, Jeunet FS, Hartmann D, (1992). Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr 55: 309S-313S.
80. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, et al. (1999). Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282: 1568-1575.
81. Hida T, Takahashi E, Shikata K, Hirohashi T, Sawai T, Seiki T, et al. (2006). Chronic intracerebroventricular administration of relaxin-3 increases body weight in rats. J Recept Signal Transduct Res 26: 147-158.
82. Hoever P, Dorffner G, Benes H, Penzel T, Danker-Hopfe H, Barbanoj MJ, et al. (2012). Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin Pharmacol Ther 91: 975-985.
83. Hommel JD, Trinko R, Sears RM, Georgescu D, Liu Z-W, Gao X-B, et al. (2006). Leptin receptor signaling in midbrain dopamine neurons regulates feeding. Neuron 51: 801-810.
84. Hostetler ED, Sanabria-Bohorquez S, Fan H, Zeng Z, Gantert L, Williams M, et al. (2011). Synthesis, characterization, and monkey positron emission tomography (PET) studies of [18F]Y1-973, a PET trace for the neuropeptide Y Y1 receptor. Neuroimaging 54: 2635-2642.
85. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, et al. (1997). Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88: 131-141.
86. Ioannides-Demos LL, Piccenna L, McNeil JJ, (2011). Pharmacotherapies for obesity: past, current and future therapies. J Obes 2011: 179674. DOI: 10.1155/2011/179674.
87. James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, et al. (2000). Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 356: 2119-2125.
88. Johansson A, Fredriksson R, Winnergren S, Hulting AL, Schioth HB, Lindblom J, (2008). The relative impact of chronic food restriction and acute food deprivation on plasma hormone levels and hypothalamic neuropeptide expression. Peptides 29: 1588-1595.
89. Jureus A, Cunningham MJ, McClain ME, Clifton DK, Steiner RA, (2000). Galanin-like peptide (GALP) is a target for regulation by leptin in the hypothalamus of the rat. Endocrinology 141: 2703-2706.
90. Jureus A, Cunningham MJ, Li D, Johnson LL, Krasnow SM, Teklemichael DN, et al. (2001). Distribution and regulation of galanin-like peptide (GALP) in the hypothalamus of the mouse. Endocrinology 142: 5140-5144.
91. Kakui N, Tanaka J, Tabata Y, Asai K, Masuda N, Miyara T, et al. (2006). Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-Tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl- ethyl)-urea Hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor. J Pharmacol Exp Ther 317: 562-570.
92. Kameda M, Kobayashi K, Ito H, Miyazoe H, Tsujino T, Nakama C, et al. (2009). Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity. Bioorg Med Chem Lett 19: 4325-4329.
93. Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Wakabayashi I, (2001). Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes 50: 2438-2443.
94. Kanatani A, Ishihara A, Asahi S, Tanaka T, Ozaki S, Ihara M, (1996). Potent neuropeptide Y Y1 receptor antagonist, 1229U91: blockade of neuropeptide Y-induced and physiological food intake. Endocrinology 137: 3177-3182.
95. Kanatani A, Hata M, Mashiko S, Ishihara A, Okamoto O, Haga Y, et al. (2001). A typical Y1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist, J-115814. Mol Pharmacol 59: 501-505.
96. Kievit P, Halem HA, Pranger L, Cowley MA, Marks DL, Grove KL, et al. (2010). A novel MC4R agonist reduces body weight and improves glucose homeostasis in high fat diet induced obese rhesus macaques. Endocr Rev 31 (3 Suppl. 1): P2-P257.
97. Kim SH, Lee YM, Jee SH, Nam CM, (2003). Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 11: 1116-1123.
98. Klein R, Nanduri V, Jing S, Lamballe F, Tapley P, Bryant S, et al. (1991). The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell 66: 395-403.
99. Knigge KM, Wagner JE, (1997). Melanin-concentrating hormone (MCH) involvement in pentylenetetrazole (PTZ)-induced seizure in rat and guinea pig. Peptides 18: 1095-1097.
100. Kohno D, Gao H-Z, Muroya S, Kikuyama S, Yada T, (2003). Ghrelin directly interacts with neuropeptide-Y-containing neurons in the rat arcuate nucleus. Diabetes 52: 948-956.
101. Komori T, Morikawa Y, Nanjo K, Senba E, (2006). Induction of brain-derived neurotrophic factor by leptin in the ventromedial hypothalamus. Neuroscience 139: 1107-1115.
102. Kopelman PG, (2000). Obesity as a medical problem. Nature 404: 635-643.
103. Kowalski TJ, Farley C, Cohen-Williams ME, Varty G, Spar BD, (2004). Melanin-concentrating hormone-1 receptor antagonism decreases feeding be reducing meal size. Eur J Pharmacol 497: 41-47.
104. Krishna R, Gumbiner B, Stevens C, Musser B, Mallick M, Suryawanshi S, et al. (2009). Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther 86: 659-666.
105. Kristensen P, Judge ME, Thim L, Ribel U, Christjansen KN, Wulff BS, et al. (1998). Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393: 72-76.
106. Krude H, Biebermann H, Schnabel D, Tansek MZ, Theunissen P, Mullis PE, et al. (2003). Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10. J Clin Endocrinol Metab 88: 4633-4640.
107. Kuei C, Sutton S, Bonaventure P, Pudiak C, Shelton J, Zhu J, et al. (2007). R3(BΔ23-27)R/I5 chimeric peptide, a selective antagonist for GPCR135 and GPCR142 over relaxin receptor LGR7. J Biol Chem 282: 25425-25435.
108. Kym PR, Souers AJ, Campbell TJ, Lynch JK, Judd AS, Iyengar R, et al. (2006). Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists. J Med Chem 49: 2339-2352.
109. Lambert PD, Anderson KD, Sleeman MW, Wong V, Tan J, Hijarunguru A, et al. (2001). Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci U S A 98: 4652-4657.
110. Lang R, Gundlach AL, Kofler B, (2007). The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther 115: 177-207.
111. Larm JA, Gundlach AL, (2000). Galanin-like peptide (GALP) mRNA expression is restricted to arcuate nucleus of hypothalamus in adult male rat brain. Neuroendocrinology 72: 67-71.
112. Lawrence CB, Baudoin FM, Luckman SM, (2002). Centrally administered galanin-like peptide modifies food intake in the rat: a comparison with galanin. J Neuroendocrinol 14: 853-860.
113. de Lecea L, Kilduff TS, Peyron C, Gao X-B, Foye PE, Danielson PE, et al. (1998). The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 95: 322-327.
114. Leibel RL, (1990). Is obesity due to a heritable difference in 'set point' for adiposity? West J Med 153: 429-431.
115. Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengerer B, Masiakowski P, et al. (1989). Molecular cloning and expression of brain-derived neurotrophic factor. Nature 341: 149-152.
116. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, et al. (2005). Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142: 532-546.
117. Lin LF, Armes LG, Sommer A, Smith DJ, Collins F, (1990). Isolation and characterization of ciliary neurotrophic factor from rabbit sciatic nerves. J Biol Chem 265: 8942-8947.
118. Liu C, Chen J, Sutton S, Roland B, Kuei C, Farmer N, et al. (2003a). Identification of relaxin-3/INSL7 as a ligand for GPCR142. J Biol Chem 278: 50765-50770.
119. Liu C, Eriste E, Sutton S, Chen J, Roland B, Kuei C, et al. (2003b). Identification of relaxin-3/INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135. J Biol Chem 278: 50754-50764.
120. Ludwig DS, Tritos NA, Mastaitis JW, Kulkarni R, Kokkotou E, Elmquist J, et al. (2001). Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J Clin Invest 107: 379-386.
121. Luquet S, Perez FA, Hnasko TS, Palmiter RD, (2005). NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. Science 310: 683-685.
122. Luthin DR, (2007). Anti-obesity effects of small molecule melanin-concentrating hormone receptor1 (MCHR1) antagonists. Life Sci 81: 423-440.
123. Lynch JK, Freeman JC, Judd AS, Iyengar R, Mulhern M, Zhao G, et al. (2006). Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety. J Med Chem 49: 6569-6584.
124. McGowan BMC, Stanley SA, Smith KL, White NE, Connolly MM, Thompson EL, et al. (2005). Central relaxin-3 administration causes hyperphagia in male Wistar rats. Endocrinology 146: 3295-3300.
125. McGowan BM, Stanley SA, Smith KL, Minnion JS, Donovan J, Thompson EL, et al. (2006). Effects of acute and chronic relaxin-3 on food intake and energy expenditure in rats. Regul Pept 136: 72-77.
126. Marsh DJ, Hollopeter G, Kafer KE, Palmiter RD, (1998). Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med 4: 718-721.
127. Marsh DJ, Weingarth DT, Novi DE, Chen HY, Trumbauer ME, Chen AS, et al. (2002). Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci U S A 99: 3240-3245.
128. Mashiko S, Ishihara A, Iwaasa H, Moriya R, Kitazawa H, Mitobe Y, et al. (2008). Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine. Obesity 16: 1510-1515.
129. Mashiko S, Moriya R, Ishihara A, Gomori A, Matsushita H, Egashira S, et al. (2009). Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis. Eur J Pharmacol 615: 113-117.
130. Matsumoto Y, Watanabe T, Adachi Y, Itoh T, Ohtaki T, Onda H, et al. (2002). Galanin-like peptide stimulates food intake in the rat. Neurosci Lett 322: 67-69.
131. Miller KJ, Murphy BJ, Pelleymounter MA, (2004). Central G-protein coupled receptors (GPCR)s as molecular targets for the treatment of obesity: assets, liabilities and development status. Curr Drug Target CNS Neurol Disord 3: 357-377.
132. Moore NA, Surman M, Guzzo P, Sargent BJ, Silverman MH, Blundell J, et al. (2011). MCH1 receptor antagonist, ALB-127158(a): phase I safety, tolerability and activity in lean and overweight volunteers. AMRI, Albany NY, USA.
133. Murphy KG, Dhillo WS, Bloom SR, (2006). Gut peptides in the regulation of food intake and energy homeostasis. Endocr Rev 27: 719-727.
134. NCATS (2012). BMS-830216 [online] Available at: http://www.ncats.nih.gov/ files/BMS-830216.pdf (accessed 15 August 2012).
135. Neurogen (2007). Neurogen announces results of first-in-human trial for new approach to treating obesity [press release], 2 May 2007, Available at: http://www.businesswire.com/news/home/20070502005240/en/Neurogen-Announces- Results-First-in-Human-Trial-Approach-Treating (Accessed 15 August 2012).
136. Nicholson JR, Peter JC, Lecourt AC, Barde YA, Hofbauer KG, (2007). Melanocortin-4 receptor activation stimulates hypothalamic brain-derived neurotrophic factor release to regulate food intake, body temperature and cardiovascular function. J Neuroendocrinol 19: 974-982.
137. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E, (2000). Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355: 39-40.
138. Ohtaki T, Kumano S, Ishibashi Y, Ogi K, Matsui H, Harada M, et al. (1999). Isolation and cDNA cloning of a novel galanin-like peptide (GALP) from porcine hypothalamus. J Biol Chem 274: 37041-37045.
139. Ollmann MM, Wilson BD, Yang Y-K, Kerns JA, Chen Y, Gantz I, et al. (1997). Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278: 135-138.
140. Omori N, Kouyama N, Yukimasa A, Watanabe K, Yokota Y, Tanioka H, et al. (2012). Hit to lead SAR study on benzoxazole derivatives for an NPY Y5 antagonist. Bioorg Med Chem Lett 22: 2020-2023.
141. Owen RT, Castaner R, Bolos J, Estivill C, (2009). Almorexant. Drugs Future 34: 5-10.
142. Palatin Technologies (2012). Palatin Technologies announces halting of phase I clinical trial of obesity compound in AstraZeneca Research Collaboration. [press release], 19 June 2012. Available at: http://www.palatin. com (accessed 15 August 2012).
143. Pedrazzini T, Seydoux J, Kunstner P, Aubert JF, Grouzmann E, Beermann F, et al. (1998). Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med 4: 722-726.
144. Pelleymounter MA, Cullen MJ, Wellman CL, (1995). Characteristics of BDNF-induced weight loss. Exp Neurol 131: 229-238.
145. Peterson WM, Wang Q, Tzekova R, Wiegand SJ, (2000). Ciliary neurotrophic factor and stress stimuli activate the Jak-STAT pathway in retinal neurons and glia. J Neurosci 20: 4081-4090.
146. Plodkowski RA, Nguyen Q, Sundaram U, Nguyen L, Chau DL, St Jeor S, (2009). Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert Opin Pharmacother 10: 1069-1081.
147. Puopolo A, Heshka S, Karmally W, Alvarado R, Kakudo S, Ochiai T, et al. (2009). A yearlong study of the efficacy and safety of 0, 800, or 1,600 mg/day of velneperit (S-2367) with a reduced calorie diet (RCD) in obese subjects. In: Obesity Soc. Ann. Sci. Meeting. pp 214-P. Washington DC.
148. Qian S, Chen H, Weingarth D, Trumbauer ME, Novi DE, Guan X, et al. (2002). Neither agouti-related protein nor neuropeptide Y is critically required for the regulation of energy homeostasis in mice. Mol Cell Biol 22: 5027-5035.
149. Qu D, Ludwig DS, Gammeltoft S, Piper M, Pelleymounter MA, Cullen MJ, et al. (1996). A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 380: 243-247.
150. Rhythm Pharmaceuticals (2011). RM-493: MC4R peptide therapeutic. [online] Available at: http://www.rhythmtx.com/PROGRAMS/RM493.html (accessed 15 August 2012).
151. Rios M, Fan G, Fekete C, Kelly J, Bates B, Kuehn R, et al. (2001). Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol Endocrinol 15: 1748-1757.
152. Rossi M, Kim MS, Morgan DG, Small CJ, Edwards CM, Sunter D, et al. (1998). A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology 139: 4428-4431.
153. Sahu A, Kalra PS, Kalra SP, (1988). Food deprivation and ingestion induce reciprocal changes in neuropeptide Y concentrations in the paraventricular nucleus. Peptides 9: 83-86.
154. Sahu A, Dube MG, Phelps CP, Sninsky CA, Kalra PS, Kalra SP, (1995). Insulin and insulin-like growth factor II suppress neuropeptide Y release from the nerve terminals in the paraventricular nucleus: a putative hypothalamic site for energy homeostasis. Endocrinology 136: 5718-5724.
155. Saito Y, Nagasaki H, (2008). The melanin-concentrating hormone system and its physiological functions. Results Probl Cell Differ 46: 159-179.
156. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and g protein-coupled receptors that regulate feeding behavior. Cell 92: 573-585.
157. Sato N, Jitsuoka M, Shibata T, Hirohashi T, Nonoshita K, Moriya M, et al. (2008). (9S)-9-(2-hydroxy-4,4-dimethyl-6-oxo-1-cyclohexen-1-yl)-3,3-dimethyl-2, 3,4,9-tetrahydro-1H-xanthen-1-one, a selective and orally active neuropeptide Y Y5 receptor antagonist. J Med Chem 51: 4765-4770.
158. Satoh N, Ogawa Y, Katsuura G, Hayase M, Tsuji T, Imagawa K, et al. (1997). The arcuate nucleus as a primary site of satiety effect of leptin in rats. Neurosci Lett 224: 149-152.
159. Schwartz MW, Sipols AJ, Marks JL, Sanacora G, White JD, Scheurink A, et al. (1992). Inhibition of hypothalamic neuropeptide Y gene expression by insulin. Endocrinology 130: 3608-3616.
160. Sendtner M, Arakawa Y, Stockli KA, Kreutzberg GW, Thoenen H, (1991). Effect of ciliary neurotrophic factor (CNTF) on motoneuron survival. J Cell Sci Suppl 15: 103-109.
161. Shiba K, Kageyama H, Takenoya F, Shioda S, (2010). Galanin-like peptide and the regulation of feeding behaviour and energy metabolism. FEBS J 277: 5006-5013.
162. Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E, (1998). Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 396: 670-674.
163. Sipols AJ, Baskin DG, Schwartz MW, (1995). Effect of intracerebroventricular insulin infusion on diabetic hyperphagia and hypothalamic neuropeptide gene expression. Diabetes 44: 147-151.
164. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, et al. (1998). Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 352: 167-172.
165. Smith AI, Funder JW, (1988). Proopiomelanocortin processing in the pituitary, central nervous system, and peripheral tissues. Endocr Rev 9: 159-179.
166. Smith D, Heshka S, Karmally W, Doepner D, Narukawa Y, Ochiai T, et al. (2009). A yearlong study of the efficacy and safety of placebo or 1,600 mg/day of velneperit (S-2367) with an initial 6-week low calorie diet (LCD) in obese subjects. Obesity Soc. Ann. Sci. Meeting. pp 221-P.
167. Smith CM, Shen P-J, Banerjee A, Bonaventure P, Ma S, Bathgate RAD, et al. (2010a). Distribution of relaxin-3 and RXFP3 within arousal, stress, affective, and cognitive circuits of mouse brain. J Comp Neurol 518: 4016-4045.
168. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. (2010b). Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 363: 245-256.
169. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al. (2010). Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 42: 937-948.
170. Stanley BG, Leibowitz SF, (1984). Neuropeptide Y: stimulation of feeding and drinking by injection into the paraventricular nucleus. Life Sci 35: 2635-2642.
171. Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF, (1986). Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 7: 1189-1192.
172. Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L, et al. (1995). The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 377: 530-532.
173. Sudo S, Kumagai J, Nishi S, Layfield S, Ferraro T, Bathgate RAD, et al. (2003). H3 relaxin is a specific ligand for LGR7 and activates the receptor by interacting with both the ectodomain and the exoloop 2. J Biol Chem 278: 7855-7862.
174. Sutton SW, Shelton J, Smith C, Williams J, Yun S, Motley T, et al. (2009). Metabolic and neuroendocrine responses to RXFP3 modulation in the central nervous system. Ann N Y Acad Sci 1160: 242-249.
175. Takatsu Y, Matsumoto H, Ohtaki T, Kumano S, Kitada C, Onda H, et al. (2001). Distribution of galanin-like peptide in the rat brain. Endocrinology 142: 1626-1634.
176. Takekawa S, Asami A, Ishihara Y, Terauchi J, Kato K, Shimomura Y, et al. (2002). T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist. Eur J Pharmacol 438: 129-135.
177. Tan CP, Sano H, Iwaasa H, Pan J, Sailer AW, Hreniuk DL, et al. (2002). Melanin-concentrating hormone receptor subtypes 1 and 2: species-specific gene expression. Genomics 79: 785-792.
178. Tan HM, Gundlach AL, Morris MJ, (2005). Exaggerated feeding response to central galanin-like peptide administration in diet-induced obese rats. Neuropeptides 39: 333-336.
179. Tanaka M, Iijima N, Miyamoto Y, Fukusumi S, Itoh Y, Ozawa H, et al. (2005). Neurons expressing relaxin 3/INSL 7 in the nucleus incertus respond to stress. Eur J Neurosci 21: 1659-1670.
180. Tang-Christensen M, Holst JJ, Hartmann B, Vrang N, (1999). The arcuate nucleus is pivotal in mediating the anorectic effects of centrally administered leptin. Neuroreport 10: 1183-1187.
181. The ALS CNTF Treatment Study Group (1996). A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 46: 1244-1249.
182. The BDNF Study Group (1999). A controlled trial of recombinant methionyl human BDNF in ALS: (Phase III). Neurology 52: 1427-1433.
183. Tokita S, Chemelli RM, Willie JT, Yanagisawa M, (2001). Behavioural characterization of orexin-2 receptor (OX2R) knockout mice [Abstract]. Sleep 24 (suppl.): A20.
184. Topol EJ, Bousser M-G, Fox KAA, Creager MA, Despres J-P, Easton JD, et al. (2010). Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 376: 517-523.
185. Tsuda K, Yokoo H, Goldstein M, (1989). Neuropeptide Y and galanin in norepinephrine release in hypothalamic slices. Hypertension 14: 81-86.
186. Tsujii S, Bray GA, (1989). Acetylation alters the feeding response to MSH and beta-endorphin. Brain Res Bull 23: 165-169.
187. Vaisse C, Clement K, Guy-Grand B, Froguel P, (1998). A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat Genet 20: 113-114.
188. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P, (2000). Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 106: 253-262.
189. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S, (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365: 1389-1397.
190. VIVUS (2012). VIVUS provides update on timing of European decision for qnexa. [press release], 5 June 2012, Available at: http://ir.vivus.com/ releasedetail.cfm?ReleaseID=679994 (accessed 15 August 2012).
191. Wang C, Bomberg E, Billington C, Levine A, Kotz CM, (2007). Brain-derived neurotrophic factor in the hypothalamic paraventricular nucleus increases energy expenditure by elevating metabolic rate. Am J Physiol Regul Integr Comp Physiol 293: R992-R1002.
192. Wang C, Godar RJ, Billington CJ, Kotz CM, (2010). Chronic administration of brain-derived neurotrophic factor in the hypothalamic paraventricular nucleus reverses obesity induced by high-fat diet. Am J Physiol Regul Integr Comp Physiol 298: R1320-R1332.
193. van der Westhuizen ET, Halls ML, Samuel CS, Bathgate RAD, Unemori EN, Sutton SW, et al. (2008). Relaxin family peptide receptors-from orphans to therapeutic targets. Drug Discov Today 13: 640-651.
194. Woods SC, Figlewicz DP, Madden L, Porte D, Jr, Sipols AJ, Seeley RJ, (1998). NPY and food intake: discrepancies in the model. Regul Pept 75-76: 403-408.
195. World Health Organization (2011). Obesity and overweight. [online] Available at: http://www.who.int/mediacentre/factsheets/fs311/en/index.html (accessed 15 August 2012).
196. Xu B, Goulding EH, Zang K, Cepoi D, Cone RD, Jones KR, et al. (2003). Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci 6: 736-742.
197. Xu AW, Kaelin CB, Morton GJ, Ogimoto K, Stanhope K, Graham J, et al. (2005). Effects of hypothalamic neurodegeneration on energy balance. PLoS Biol 3: e415.
198. Yaswen L, Diehl N, Brennan MB, Hochgeschwender U, (1999). Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 5: 1066-1070.
199. Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG, O'Rahilly S, (1998). A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 20: 111-112.
200. Yeo GSH, Hung CCC, Rochford J, Keogh J, Gray J, Sivaramakrishnan S, et al. (2004). A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci 7: 1187-1189.
201. Yukioka H, Kawanishi Y, Katsuura G, Takenaka H, Hara S, (2006). A potent and selective neuropeptide Y Y5 receptor antagonist, S-2367, attenuates the development of diet-induced obesity in mice. NAASO 2006 Annual Scientific Meeting.
202. Yulyaningsih E, Zhang L, Herzog H, Sainsbury A, (2011). NPY receptors as potential targets for anti-obesity drug development. Br J Pharmacol 163: 1170-1202.
203. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B, (1993). Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 133: 1753-1758.